afamelanotide
Dermatologicals (D02)US regulatory status: approved. Molecular target: Melanocyte-stimulating hormone receptor.
- Target
- Melanocyte-stimulating hormone receptor
- Mechanism
- Melanocortin receptor 1 agonist
pharma · Vitiligo · Erythropoietic Protoporphyria (EPP)
CLINUVEL PHARMACEUTICALS
Clinuvel Europe Limited
CLINUVEL PHARMACEUTICALS drug portfolio — 3 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Melbourne, AU HQ
2001 Founded
83 Employees
EMA registrant Type
Company details
- Status
- Public
- HQ
- Melbourne, AU
- Founded
- 2001
- Employees
- 83
- Programs
- 5
- Drugs
- 3
- Patents
- 0
CLINUVEL PHARMACEUTICALS pipeline
Portfolio lens on 3 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
CLINUVEL PHARMACEUTICALS drug portfolio — 3 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
Development asset linked to CLINUVEL PHARMACEUTICALS in public FDA and regional records.
-
Development asset linked to CLINUVEL PHARMACEUTICALS in public FDA and regional records.